Trium Capital LLP
Q3 2025 13F-HR Holdings
Net value change ($000)
-146,171
(-36.4%)
New positions
18
Sold out positions
23
Turnover %
137.4%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2025
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| COOP | 39,460 | NEW |
| ASHR | 31,955 | NEW |
| EWW | 11,059 | 136.9% |
| VRNA | 10,654 | NEW |
| EEM | 10,183 | NEW |
| TASK | 7,215 | NEW |
| ALMS | 4,513 | 56.8% |
| FSLR | 2,528 | 1221.3% |
| PNR | 1,388 | NEW |
| OC | 1,206 | 86.4% |
Top Reduces (Value $000, Stocks/ETFs)
| EWC | -71,726 | -100.0% |
| SpringWorks Therapeutics, Inc. | -37,003 | -100.0% |
| BPMC | -30,776 | -100.0% |
| AGS | -23,284 | -100.0% |
| AKX | -14,568 | -100.0% |
| VNM | -13,601 | -100.0% |
| EWZ | -12,954 | -46.1% |
| INOZYME PHARMA INC | -12,694 | -100.0% |
| ACI | -11,223 | -34.9% |
| EWY | -10,528 | -39.1% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
882
(0.3% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|